JP5725649B2 - Composition containing tomorrow chalcone and isoflavone - Google Patents
Composition containing tomorrow chalcone and isoflavone Download PDFInfo
- Publication number
- JP5725649B2 JP5725649B2 JP2011028361A JP2011028361A JP5725649B2 JP 5725649 B2 JP5725649 B2 JP 5725649B2 JP 2011028361 A JP2011028361 A JP 2011028361A JP 2011028361 A JP2011028361 A JP 2011028361A JP 5725649 B2 JP5725649 B2 JP 5725649B2
- Authority
- JP
- Japan
- Prior art keywords
- tomorrow
- chalcone
- composition
- isoflavone
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 title claims description 94
- 235000005513 chalcones Nutrition 0.000 title claims description 94
- 239000000203 mixture Substances 0.000 title claims description 82
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 title claims description 82
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims description 52
- 235000008696 isoflavones Nutrition 0.000 title claims description 52
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 title claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- 239000000284 extract Substances 0.000 claims description 48
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical group C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 108010076365 Adiponectin Proteins 0.000 claims description 22
- 102000011690 Adiponectin Human genes 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 13
- 230000001939 inductive effect Effects 0.000 claims description 12
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 12
- 210000000416 exudates and transudate Anatomy 0.000 claims description 10
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 claims description 10
- XDKYBPGIBVMHHB-KPKJPENVSA-N 4-Hydroxyderricin Chemical group OC1=C(CC=C(C)C)C(OC)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 XDKYBPGIBVMHHB-KPKJPENVSA-N 0.000 claims description 9
- XDKYBPGIBVMHHB-UHFFFAOYSA-N 4-Hydroxyderricin Natural products OC1=C(CC=C(C)C)C(OC)=CC=C1C(=O)C=CC1=CC=C(O)C=C1 XDKYBPGIBVMHHB-UHFFFAOYSA-N 0.000 claims description 9
- 235000007240 daidzein Nutrition 0.000 claims description 9
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 8
- -1 biocanin A Natural products 0.000 claims description 7
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 claims description 7
- 235000008466 glycitein Nutrition 0.000 claims description 7
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 claims description 7
- 238000000956 solid--liquid extraction Methods 0.000 claims description 7
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 claims description 5
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 claims description 5
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims description 5
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims description 5
- XJTZHGNBKZYODI-UHFFFAOYSA-N Glycitin Natural products OCC1OC(Oc2ccc3OC=C(C(=O)c3c2CO)c4ccc(O)cc4)C(O)C(O)C1O XJTZHGNBKZYODI-UHFFFAOYSA-N 0.000 claims description 5
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims description 5
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims description 5
- LRSMBOSQWGHYCW-MDGZPELGSA-N (e)-1-[3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound CC(C)=CCC\C(C)=C\CC1=C(O)C=CC(C(=O)\C=C\C=2C=CC(O)=CC=2)=C1O LRSMBOSQWGHYCW-MDGZPELGSA-N 0.000 claims description 3
- LRSMBOSQWGHYCW-OAEBONLZSA-N Xanthoangelol Natural products CC(C)=CCC\C(C)=C/CC1=C(O)C=CC(C(=O)\C=C\C=2C=CC(O)=CC=2)=C1O LRSMBOSQWGHYCW-OAEBONLZSA-N 0.000 claims description 3
- LRSMBOSQWGHYCW-UHFFFAOYSA-N xanthoangerol Natural products CC(C)=CCCC(C)=CCC1=C(O)C=CC(C(=O)C=CC=2C=CC(O)=CC=2)=C1O LRSMBOSQWGHYCW-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 description 22
- 239000000843 powder Substances 0.000 description 19
- 235000013305 food Nutrition 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000005469 granulation Methods 0.000 description 12
- 230000003179 granulation Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 150000001788 chalcone derivatives Chemical class 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 244000068988 Glycine max Species 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 240000003768 Solanum lycopersicum Species 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 4
- 101000775476 Mus musculus Adiponectin Proteins 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001789 chalcones Chemical class 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 235000020712 soy bean extract Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000006539 genistein Nutrition 0.000 description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
- 229940045109 genistein Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108700009884 Hypoadiponectinemia Proteins 0.000 description 2
- 241001470257 Nagara Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 2
- 244000250129 Trigonella foenum graecum Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- SERLAGPUMNYUCK-URHLDCCQSA-N (2R,3S,4R,5S)-6-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-URHLDCCQSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 241000962514 Alosa chrysochloris Species 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000005320 Coleus barbatus Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000018453 Curcuma amada Nutrition 0.000 description 1
- 241001512940 Curcuma amada Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001755 Kefiran Polymers 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000013500 Melia azadirachta Nutrition 0.000 description 1
- 244000237986 Melia azadirachta Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000131459 Plectranthus barbatus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020235 chia seed Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940075071 maitake extract Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003128 phytoestrogenic effect Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229960001109 policosanol Drugs 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、明日葉のカルコン及びイソフラボンを含有する機能性組成物に関する。 The present invention relates to a functional composition containing chalcone of tomorrow and isoflavone.
近年、わが国では食生活が豊かになり、動脈硬化や糖尿病のような生活習慣病が急増している。加齢によって基礎代謝量が減少しているにも拘わらず脂肪や糖類を過剰摂取し、さらには運動不足の要因も重なり、肥満体型になることが、生活習慣病の原因として指摘されている。 In recent years, eating habits have been enriched in Japan, and lifestyle-related diseases such as arteriosclerosis and diabetes have been rapidly increasing. It has been pointed out as a cause of lifestyle-related diseases that fats and sugars are excessively consumed even though the basal metabolic rate is reduced by aging, and further, the factors of lack of exercise overlap and become obese.
アディポネクチンは、脂肪細胞から特異的に産生、分泌される２４４残基のアミノ酸からなるタンパク質である。アディポネクチンは、糖や脂肪の代謝に密接に関与しており、肥満や肥満に伴う循環器系疾患（動脈硬化症、高脂血症等）及び糖尿病等の生活習慣病の患者においては血中のアディポネクチン濃度が低下していることが知られている。これらのことから、アディポネクチンの産生を促進することが、肥満、循環器系疾患、及び糖尿病等の予防又は治療に有効であると考えられている。 Adiponectin is a protein consisting of 244 amino acids that is specifically produced and secreted from adipocytes. Adiponectin is closely involved in the metabolism of sugar and fat, and it is found in blood in patients with obesity, cardiovascular diseases associated with obesity (arteriosclerosis, hyperlipidemia, etc.) and lifestyle-related diseases such as diabetes. It is known that the adiponectin concentration is decreased. From these facts, it is considered that promoting the production of adiponectin is effective in preventing or treating obesity, cardiovascular diseases, diabetes and the like.
一方、明日葉のカルコンにはさまざまな健康促進効果があることが知られており、明日葉のカルコンには抗糖尿病作用、脂肪前駆細胞の脂肪細胞への分化誘導作用、及び脂肪細胞へのグルコース取り込み促進作用があることが知られている（特許文献１）。また、明日葉のカルコンがアディポネクチン産生促進作用を有することも知られている（特許文献２）。また、イソフラボンは、抗酸化作用と植物エストロゲン作用を併せ持つことが広く知られており、大豆由来のイソフラボンがアディポネクチンの分泌亢進作用を有することも報告されている（非特許文献１）。 On the other hand, tomorrow's chalcones are known to have various health promoting effects, and tomorrow's chalcones have anti-diabetic effects, differentiation-inducing action of adipose precursor cells into adipocytes, and glucose into adipocytes. It is known that there is an action of promoting uptake (Patent Document 1). It is also known that tomorrow chalcone has an adiponectin production promoting action (Patent Document 2). In addition, it is widely known that isoflavones have both an antioxidant action and a phytoestrogenic action, and it has been reported that isoflavones derived from soybean have an adiponectin secretion enhancing action (Non-patent Document 1).
本発明の目的は、優れたアディポネクチン産生誘導作用を有する組成物を提供することにある。 An object of the present invention is to provide a composition having an excellent adiponectin production-inducing action.
上記のような状況下において、本発明者らは鋭意研究を重ねた結果、明日葉のカルコンとイソフラボンとを同時に用いることにより、それぞれを単独で使用した場合に比べて著しく高い、相乗的なアディポネクチン産生誘導作用を示すことを見出し、本発明を完成させた。
すなわち、本発明は、
［１］明日葉のカルコン及びイソフラボンを含有する組成物、
［２］明日葉のカルコン及び大豆由来のイソフラボンを含有する組成物である［１］の組成物、
［３］大豆由来のイソフラボンが、ダイゼイン、ビオカニンＡ、グリシテイン、ダイジン、グリシチン及びゲニスチンからなる群より選択された少なくとも一種である［２］の組成物、
［４］明日葉抽出物及びイソフラボンを含有する組成物である［１］の組成物、
［５］明日葉抽出物が、含水エタノールを溶媒とした固液抽出によって明日葉から得られた抽出物である［４］の組成物、
［６］明日葉からの滲出物及びイソフラボンを含有する組成物である［１］の組成物、
［７］明日葉のカルコンが４−ヒドロキシデリシン及び／又はキサントアンゲロールである［１］の組成物、
［８］［１］〜［７］のいずれかの組成物を含有する食品、
［９］［１］〜［７］のいずれかの組成物を含有する医薬、並びに
［１０］［１］〜［７］のいずれかの組成物を含有するアディポネクチン産生誘導剤、
に関する。
Under the circumstances as described above, as a result of intensive studies, the present inventors have used synergistic adiponectin that is significantly higher than the case where each is used alone by using chalcone of tomorrow and isoflavone at the same time. The present invention has been completed by finding that it has a production-inducing action.
That is, the present invention
[1] A composition containing chalcone of tomorrow and isoflavone,
[2] The composition according to [1], which comprises a chalcone of tomorrow and an isoflavone derived from soybean,
[3] The composition according to [2], wherein the isoflavone derived from soybean is at least one selected from the group consisting of daidzein, biocanin A, glycitein, daidzin, glycitin, and genistin.
[4] The composition of [1], which is a composition containing an extract of tomorrow and isoflavones,
[5] The composition of [4], wherein the extract of tomorrow is an extract obtained from tomorrow by solid-liquid extraction using hydrous ethanol as a solvent,
[6] The composition of [1], which is a composition containing exudate from tomorrow leaves and isoflavone,
[7] The composition of [1], wherein the chalcone of tomorrow is 4-hydroxyderricin and / or xanthoangelol,
[8] A food containing the composition according to any one of [1] to [7],
[9] A medicament containing the composition of any one of [1] to [7], and an adiponectin production inducer containing the composition of any of [10] [1] to [7],
About.
本発明の組成物は、優れたアディポネクチン産生誘導作用を奏するため、肥満や肥満に伴う循環器系疾患（動脈硬化症、高脂血症等）及び糖尿病等の生活習慣病の予防、改善、及び／又は治療に有用である。 Since the composition of the present invention has an excellent adiponectin production-inducing action, obesity and prevention of circulatory diseases associated with obesity (arteriosclerosis, hyperlipidemia, etc.) and lifestyle-related diseases such as diabetes, and Useful for treatment.
以下に、本発明について詳細に説明する。 The present invention is described in detail below.
本発明の組成物は、明日葉のカルコン及びイソフラボンを含有し、明日葉のカルコンやイソフラボンをそれぞれ単独で使用した場合に比べて著しく高い、相乗的なアディポネクチン産生誘導作用を示す。 The composition of the present invention contains tomorrow leaf chalcone and isoflavone, and exhibits a synergistic adiponectin production-inducing action that is significantly higher than when tomorrow leaf chalcone and isoflavone are used alone.
明日葉（学名Ａｎｇｅｌｉｃａ ｋｅｉｓｋｅｉ）とは、八丈芹とも呼ばれる主に太平洋岸に自生する日本固有のセリ科の大型多年草である。また、カルコンとは、カルコン骨格を有する化合物のことを意味する。明日葉のカルコンとしては、本発明を特に限定するものではないが、４−ヒドロキシデリシン（以下、４ＨＤと記載することがある）、及びキサントアンゲロールが好適に例示される。本発明の組成物は明日葉のカルコンを高濃度で含有する。組成物中のカルコンの含量は、ＯＤＳカラムを用いたＨＰＬＣにより、標準品とのＵＶ吸収面積比によって測定することができる。なお、アシタバ中のカルコンはキサントアンゲロールと４−ハイドロキシデリシンがその大部分を占めるため、本願においては、キサントアンゲロールと４−ハイドロキシデリシンの総含有量を特定することでカルコンの含量の指標とする。本発明の組成物中の明日葉のカルコンの含量としては、０．１〜６０重量％が好適に例示され、０．５〜４０重量％がより好適に例示され、１〜２０重量％がさらにより好適に例示される。 Tomorrow (scientific name: Angelica keiskei) is a large perennial plant that is native to Japan and is native to the Pacific coast, also called Hachijo-an. The chalcone means a compound having a chalcone skeleton. As the chalcone of tomorrow, although the present invention is not particularly limited, 4-hydroxyderricin (hereinafter sometimes referred to as 4HD) and xanthoangelol are preferably exemplified. The composition of the present invention contains a high concentration of tomorrow leaf chalcone. The chalcone content in the composition can be measured by HPLC using an ODS column by the UV absorption area ratio with a standard product. The chalcone in Ashitaba occupies most of xanthangelol and 4-hydroxyderricin. Therefore, in the present application, by specifying the total content of xanthangelol and 4-hydroxyderricin, It is used as an index of content. The content of chalcone of tomorrow in the composition of the present invention is preferably 0.1 to 60% by weight, more preferably 0.5 to 40% by weight, and further 1 to 20% by weight. More preferably illustrated.
本発明の組成物に含まれる明日葉のカルコンは、明日葉のいずれの部位に含まれるものであってもよく、果実、種子、種皮、花、葉、茎、根、根茎及び／又は植物全体に由来するカルコンが使用でき、葉及び／又は茎に由来するカルコンが好適に使用できる。また、明日葉のカルコンは、カルコンを含有する明日葉の処理物として本発明の組成物に含まれていてもよい。明日葉の処理物は、特に本発明を限定するものではないが、例えば、原料の明日葉に対して何らかの加工を施したものであればよく、磨砕物、乾燥粉末、粉砕物、搾汁液、破砕物、抽出物、明日葉からの滲出物が例示される。すなわち、明日葉抽出物及びイソフラボンを含有する組成物や、明日葉からの滲出物及びイソフラボンを含有する組成物、あるいは明日葉の葉及び／又は茎並びにイソフラボンを含有する組成物も、本発明の組成物として例示される。 The chalcone of tomorrow contained in the composition of the present invention may be contained in any part of tomorrow, such as fruit, seed, seed coat, flower, leaf, stem, root, rhizome and / or whole plant. Can be used, and chalcones derived from leaves and / or stems can be preferably used. Moreover, tomorrow leaf chalcone may be contained in the composition of the present invention as a processed product of tomorrow leaf containing chalcone. The processed product of tomorrow is not particularly limited to the present invention, for example, it may be anything that has been subjected to some processing on the raw material of tomorrow, such as a ground product, a dry powder, a ground product, a juice, Examples include crushed materials, extracts, and exudates from tomorrow leaves. That is, a composition containing an extract of tomorrow leaves and isoflavones, a composition containing exudates from tomorrow leaves and isoflavones, or a composition containing leaves and / or stems of tomorrow leaves and isoflavones are also included in the present invention. Illustrated as a composition.
本明細書において抽出物とは、例えば固液抽出工程を経て得られる抽出液、並びに当該抽出液からさらに分離工程、精製工程、及び／又は乾燥工程等を経て得られた物質のことをいう。固液抽出は、公知の方法により以下のように行うことができる。例えば原料を粉砕もしくは裁断した後、溶媒を用いてバッチ式もしくは連続式で行うことができる。抽出に用いる抽出溶媒としては、特に限定はないが、水、クロロホルム、エタノール、メタノール、イソプロピルアルコール等のアルコール類、アセトン、メチルエチルケトン等のケトン類、酢酸メチル、酢酸エチル等の親水性もしくは親油性の溶媒を挙げることができ、所望により単独で、もしくは適宜混合液として用いることができる。混合液を抽出溶媒として用いる例としては、特に限定はないが、例えば各種水溶液を用いることができ、例えば１０〜９５％、好適には１５〜９０％、さらに好適には２０〜８５％のアルコール水溶液を使用することができる。特に本発明を限定するものではないが、上記のアルコール水溶液としては、含水エタノール水溶液が好ましい。 In the present specification, an extract refers to, for example, an extract obtained through a solid-liquid extraction process and a substance obtained from the extract through a separation process, a purification process, and / or a drying process. Solid-liquid extraction can be performed by a known method as follows. For example, after pulverizing or cutting the raw material, it can be carried out batchwise or continuously using a solvent. The extraction solvent used for extraction is not particularly limited, but water, chloroform, ethanol, methanol, isopropyl alcohol and other alcohols, acetone, methyl ethyl ketone and other ketones, methyl acetate, ethyl acetate and other hydrophilic or lipophilic solvents. A solvent can be mentioned, and it can be used alone or as a mixed solution as required. An example of using the mixed solution as an extraction solvent is not particularly limited. For example, various aqueous solutions can be used. For example, 10 to 95%, preferably 15 to 90%, more preferably 20 to 85% alcohol. An aqueous solution can be used. Although the present invention is not particularly limited, a water-containing ethanol aqueous solution is preferable as the alcohol aqueous solution.
抽出溶媒の量は適宜決定すればよいが、通常、原料植物に対し、使用時の原料植物の形態そのまま（例えば原料植物が生の植物であれば生の植物）の重量の、好ましくは２〜１００倍量の抽出溶媒を使用すれば良い。抽出温度も適宜、目的に応じて決定すれば良いが、水抽出の場合は通常、好ましくは４〜１３０℃、より好ましくは２５〜１００℃である。また、溶媒中にエタノールが含まれる場合は安全性の観点から４〜６０℃の範囲が好適である。抽出時間も、抽出効率を考慮し決定すればよいが、通常、好ましくは数秒〜数日間、より好ましくは５分〜２４時間の範囲となるように、原料、抽出溶媒、抽出温度を設定するのが好適である。抽出操作は、たとえば、攪拌しながら又は静置して行えばよく、また、必要に応じて数回繰り返してもよい。 The amount of the extraction solvent may be appropriately determined. Usually, the raw material plant is used in the form of the raw material plant as it is (for example, a raw plant if the raw plant is a raw plant), preferably 2 to 2 A 100-fold amount of extraction solvent may be used. The extraction temperature may be appropriately determined according to the purpose, but in the case of water extraction, it is usually preferably 4 to 130 ° C, more preferably 25 to 100 ° C. Moreover, when ethanol is contained in a solvent, the range of 4-60 degreeC is suitable from a safety viewpoint. The extraction time may be determined in consideration of the extraction efficiency. Usually, the raw material, the extraction solvent, and the extraction temperature are set so as to be preferably in the range of several seconds to several days, more preferably 5 minutes to 24 hours. Is preferred. The extraction operation may be performed, for example, while stirring or standing, and may be repeated several times as necessary.
固液抽出工程により得られた抽出液に対して、必要に応じてろ過、遠心分離、濃縮、限外ろ過、分子ふるい等の処理を施すことで、アディポネクチン産生誘導作用を有する有効成分が濃縮された抽出物を調製することができる。また、抽出物は溶媒に溶解した溶液のまま、濃縮液もしくは固形化物として本発明に使用することができる。濃縮、固形化には公知の手段が使用できる。例えば、国際公開第２００４／１１２８１７号パンフレットに記載されるように、含水エタノール水溶液により固液抽出して得られた抽出液を乾燥させ、さらに粉砕機を使用して粉砕することで、明日葉のカルコンを含有する明日葉抽出物の乾燥粉末を得ることができる。また、凍結粉砕や、凍結乾燥後粉砕することにより乾燥粉末を得てもよい。 The extract obtained by the solid-liquid extraction process is subjected to treatment such as filtration, centrifugation, concentration, ultrafiltration, molecular sieving, etc. as necessary to concentrate the active ingredient having an adiponectin production inducing action. Extracts can be prepared. In addition, the extract can be used in the present invention as a concentrated solution or a solidified product as a solution dissolved in a solvent. A well-known means can be used for concentration and solidification. For example, as described in the pamphlet of International Publication No. 2004/112817, the extract obtained by solid-liquid extraction with a water-containing ethanol aqueous solution is dried, and further pulverized using a pulverizer. A dry powder of tomorrow leaf extract containing chalcone can be obtained. Further, a dry powder may be obtained by freeze pulverization or pulverization after freeze-drying.
明日葉の滲出物は、例えば発芽してから開花前までの明日葉の茎から滲出する黄色の液体（アシタバ黄汁）を採取することにより得ることができる。明日葉の滲出物は、必要に応じて濾過、加熱殺菌などの処理を施してもよい。明日葉からの滲出物を粉末化して本発明の組成物に用いる場合には、明日葉の滲出物をそのまま乾燥・粉砕して用いてもよく、デキストリン、乳糖、結晶セルロース、二酸化ケイ素、環状オリゴ糖、サイクロデキストリン等の賦形剤を滲出物に加えた後に粉末化してもよい。明日葉からの滲出物と賦形剤との混合にあたっては、均一な混合を行うためにエタノール等の適当な溶媒を加えても良く、また、発泡を防ぐために適量の消泡剤を加えてもよい。 The exudate of tomorrow leaves can be obtained, for example, by collecting yellow liquid (Ashitaba yellow juice) that exudes from the stems of tomorrow leaves from germination to before flowering. The exudate of tomorrow may be subjected to treatments such as filtration and heat sterilization as necessary. When the exudate from tomorrow is powdered and used in the composition of the present invention, the exudate from tomorrow may be used after being dried and pulverized as it is, dextrin, lactose, crystalline cellulose, silicon dioxide, cyclic oligo An excipient such as sugar or cyclodextrin may be added to the exudate and then powdered. When mixing exudates from tomorrow with excipients, an appropriate solvent such as ethanol may be added to achieve uniform mixing, and an appropriate amount of antifoaming agent may be added to prevent foaming. Good.
本明細書においてイソフラボンとは、イソフラボン骨格を有する化合物のことを言い、例えばダイジン（Ｄａｉｄｚｉｎ）、ゲニスチン（Ｇｅｎｉｓｔｉｎ）、グリシチン（Ｇｌｙｃｉｔｉｎ）、それらのマロニル化体、アセチル化体、サクシニル化体、及びそれらのアグリコンであるダイゼイン（Ｄａｉｄｚｅｉｎ）、ゲニステイン（Ｇｅｎｉｓｔｅｉｎ）、グリシテイン（Ｇｌｙｃｉｔｅｉｎ）、並びにビオカニンＡ（Ｂｉｏｃｈａｎｉｎ Ａ）及びフォルモノネチン（Ｆｏｒｍｏｎｏｎｅｔｉｎ）等が例示される。本発明の組成物に含まれるイソフラボンとしては、大豆イソフラボンが好適に例示され、ダイゼイン、ビオカニンＡ、グリシテイン、ダイジン、グリシチン及びゲニスチンがより好適に例示される。本発明の組成物中のイソフラボン含量としては、０．１〜６０重量％が好適に例示され、０．５〜４０重量％がより好適に例示され、１〜２０重量％がさらにより好適に例示される。組成物中のイソフラボン含量は、「大豆イソフラボンを含む特定保健用食品などの取り扱いに関する指針について」（食安発第０８２３００１号）にて定められた試験法によって測定することができる。本発明に使用可能な市販の大豆イソフラボンとしては、本発明を特に限定するものではないが、フジフラボンＰ１０（フジッコ社製）、フジフラボンＳ（フジッコ社製）、フジフラボンＰ４０（フジッコ社製）、フジフラボンＣ（フジッコ社製）、及びソヤフラボン（不二製油社製）が例示される。 In this specification, isoflavone refers to a compound having an isoflavone skeleton, such as daidzin, genistin, glycitin, malonylated form, acetylated form, succinylated form, and the like. Examples of such aglycones include daidzein, genistein, glycitein, biochanin A, and formononetin. As the isoflavone contained in the composition of the present invention, soybean isoflavone is preferably exemplified, and daidzein, biocanin A, glycitein, daidzin, glycitin and genistin are more suitably exemplified. The isoflavone content in the composition of the present invention is preferably 0.1 to 60% by weight, more preferably 0.5 to 40% by weight, and even more preferably 1 to 20% by weight. Is done. The isoflavone content in the composition can be measured by a test method defined in “Guidelines for handling foods for specified health use containing soybean isoflavone” (No. 0823001). The present invention is not particularly limited as a commercially available soy isoflavone usable in the present invention. (Fujicco) and Soyaflavone (Fuji Oil Co., Ltd.) are exemplified.
本発明の組成物は、明日葉のカルコンとイソフラボンとを混合することにより得ることができる。本発明の組成物中の明日葉のカルコンとイソフラボンの含有量比としては１００：１〜１：１００が好適に例示され、１０：１〜１：１０がより好適に例示され、２：１〜１：２．５がさらにより好適に例示される。 The composition of the present invention can be obtained by mixing tomorrow leaf chalcone and isoflavone. As the content ratio of chalcone of tomorrow leaves and isoflavone in the composition of the present invention, 100: 1 to 1: 100 is preferably exemplified, 10: 1 to 1:10 is more suitably exemplified, and 2: 1 to 1: 2.5 is even more preferably exemplified.
本発明の組成物中には、これまでに例示した成分の他に、賦形剤、増粘剤、油性成分、医薬品添加剤、食品成分等の任意の成分が含まれていてもよい。本発明の組成物にこれら任意の成分が含まれる場合、その含有率は組成物の全重量に対して通常、１〜９９．９重量％、好ましくは７０〜９９重量％、より好ましくは８０〜９５重量％である。また、本発明の組成物は、好ましくは経口での摂取が可能な形状とされる。その製造にあたっては、固形状、液状の適当な担体、好ましくは薬学的に許容される担体と混合し、加工すればよい。さらに、アディポネクチン産生誘導作用やその他の生理作用を有する他の成分を添加することもできる。その形状には、特に限定はなく、固形状（粉末状、顆粒状の組成物を包含する）、液状（油状組成物を包含する）のいずれであってもよい。前記組成物は公知の加工方法により、任意の形状で製造することができる。本発明を特に限定するものではないが、例えば、明日葉のカルコンとイソフラボンとを公知の方法で造粒して粒状の固形物として使用することができる。造粒方法としては、特に限定はないが、転動造粒、攪拌造粒、流動層造粒、気流造粒、押出し造粒、圧縮成型造粒、解砕造粒、噴射造粒又は噴霧造粒等が例示される。粉状の当該処理物を液体、例えば水やアルコール等に溶解又は懸濁して液状とし、本発明の組成物として使用することもできる。さらに、タブレット状、顆粒状、カプセル状（ソフトカプセル状を含む）等の形状の経口的に摂取が容易な形状物としてもよい。本発明の組成物をカプセルに内包させる場合、公知の製剤助剤、例えばゼラチン、グリセリン、ミツロウ、グリセリン脂肪酸エステル等を用いてもよく、公知の賦形剤、例えば乳糖、コーンスターチ、加工デンプン、ビール酵母エキス、食用油脂、ショ糖脂肪酸エステル等を用いてもよい。また、本発明の組成物を顆粒状とする場合、その製造方法に特に限定はないが、例えば本発明の組成物に賦形剤として乳糖、還元麦芽糖、結晶セルロース、デキストリン、ショ糖脂肪酸エステル等を適宜混合し、流動層造粒機や押出し造粒機により造粒し、振動篩で整粒することにより製造することができる。 In the composition of this invention, arbitrary components, such as an excipient | filler, a thickener, an oil-based component, a pharmaceutical additive, a food component, may be contained other than the component illustrated so far. When these optional components are contained in the composition of the present invention, the content is usually 1 to 99.9% by weight, preferably 70 to 99% by weight, more preferably 80 to 80% by weight based on the total weight of the composition. 95% by weight. The composition of the present invention is preferably in a form that can be taken orally. In its production, it may be mixed and processed with a suitable solid or liquid carrier, preferably a pharmaceutically acceptable carrier. Furthermore, other components having an adiponectin production-inducing action and other physiological actions can be added. The shape is not particularly limited, and may be solid (including powdered and granular compositions) or liquid (including oily compositions). The composition can be produced in an arbitrary shape by a known processing method. Although this invention is not specifically limited, For example, chalcone of tomorrow and isoflavone can be granulated by a well-known method, and it can use as a granular solid. The granulation method is not particularly limited, but rolling granulation, stirring granulation, fluidized bed granulation, air flow granulation, extrusion granulation, compression molding granulation, pulverization granulation, spray granulation, spray granulation or spray granulation Examples are grains. The treated product in powder form can be dissolved or suspended in a liquid such as water or alcohol to obtain a liquid, which can be used as the composition of the present invention. Furthermore, it is good also as a shape which is easy to take orally, such as tablet shape, granule shape, and capsule shape (including soft capsule shape). When encapsulating the composition of the present invention in the capsule, known formulation aids such as gelatin, glycerin, beeswax, glycerin fatty acid ester and the like may be used, and known excipients such as lactose, corn starch, modified starch, beer Yeast extracts, edible oils and fats, sucrose fatty acid esters and the like may be used. In addition, when the composition of the present invention is granulated, the production method is not particularly limited. For example, lactose, reduced maltose, crystalline cellulose, dextrin, sucrose fatty acid ester, etc. as excipients for the composition of the present invention Are appropriately mixed, granulated with a fluidized bed granulator or an extrusion granulator, and sized with a vibrating sieve.
また、本発明の組成物は、アディポネクチン産生誘導効果、体脂肪や内臓脂肪の低減効果及び／又は脂質代謝の改善効果が知られている物質をさらに含有してもよい。例えば、
（Ａ）明日葉のカルコン及びイソフラボン、並びに
（Ｂ）カテキン、カプサイシン、トゲドコロ処理物、アスタキサンチン、エルカンプーレ、カツオペプチド、ガルシニア、カワラケツメイ、柑橘系フルーツエキス、キウイ果皮抽出物、キノコキトサン、共役リノール酸、黒大豆種皮抽出物、桑葉、ケツメイシ、コタラヒム、米ケフィラン、コレウスフォルスコリ、シッサスクアドラングラリス、ジャガイモ抽出物、植物ステロール、植物油脂乳化物（ファビュレス）、タマネギケルセチン、チアシード、ツルアラメ抽出物、ＤＨＡ結合リン脂質、ニーム、フェヌグリーク（コロハ）、ブドウレスベラトロール、ポリコサノール、マイタケ抽出物（グリスリン）、マカエキス、マンゴージンジャー、Ｌ−カルニチン酒石酸塩、α−リポ酸、α−リノレン酸、中鎖脂肪酸及びリン脂質からなる群より選択された少なくとも１種の物質を含有する組成物も本発明の態様の一つである。
In addition, the composition of the present invention may further contain substances known to have an adiponectin production-inducing effect, a body fat or visceral fat reducing effect, and / or a lipid metabolism improving effect. For example,
(A) chalcone and isoflavone of tomorrow, and (B) catechin, capsaicin, togekokoro processed product, astaxanthin, elcampure, skipjack peptide, garcinia, kawataketsumei, citrus fruit extract, kiwi peel extract, mushroom chitosan, conjugated linoleic acid, Black soybean seed coat extract, mulberry leaf, katsumeshi, kotarahim, rice kefiran, coleus forskohlii, sissasquad granulis, potato extract, plant sterol, vegetable oil emulsion (fabulous), onion quercetin, chia seed, tsuruarame extract, DHA binding Phospholipid, Neem, Fenugreek (Fenugreek), Grape resveratrol, Policosanol, Maitake extract (Glysulin), Maca extract, Mango ginger, L-carnitine tartrate, α-lipoic acid, α- A composition containing at least one substance selected from the group consisting of linolenic acid, medium chain fatty acids and phospholipids is also one aspect of the present invention.
本発明の組成物が示すアディポネクチン産生誘導作用は、例えば実施例１に示すように、脂肪細胞に本発明の組成物を作用させた後、リアルタイムＲＴ−ＰＣＲ等によりアディポネクチンのｍＲＮＡの発現率を調査することによって確認することができる。 The adiponectin production-inducing action exhibited by the composition of the present invention is, for example, as shown in Example 1, after the composition of the present invention is allowed to act on adipocytes, the expression rate of adiponectin mRNA is investigated by real-time RT-PCR or the like It can be confirmed by doing.
本発明の食品は、本発明の組成物を含む。本発明の食品は、その種類に特に限定はなく、穀物加工品、油脂加工品、大豆加工品、食肉加工品、水産製品、乳製品、野菜・果実加工品、菓子類、アルコール飲料、嗜好飲料、調味料、香辛料などの農産・林産加工品、畜産加工品、水産加工品などが挙げられる。前記食品は液体形状であってもよい。すなわち、前記の食品は飲料を包含する。本発明の組成物を含有する食品の製造法に特に限定はない。例えば、配合、調理、加工等は一般の食品のものに従えばよく、それらの製造法により製造することができ、得られた食品に前述の本発明の組成物が含有されていればよい。特に本発明を限定するものではないが、本発明の食品は、１日あたりの明日葉のカルコンの摂取量が好ましくは０．５ｍｇ〜１００ｍｇ、より好ましくは２ｍｇ〜２５ｍｇになるように、１日あたりのイソフラボンの摂取量が好ましくは０．５ｍｇ〜１００ｍｇ、より好ましくは２ｍｇ〜２５ｍｇとなるように調製するのが好ましい。 The food of the present invention contains the composition of the present invention. The food of the present invention is not particularly limited in its type, and is processed cereals, processed fats and oils, processed soybeans, processed meats, marine products, dairy products, processed vegetables and fruits, confectionery, alcoholic beverages, and beverages. , Processed agricultural products such as seasonings and spices, processed livestock products, processed fishery products, and the like. The food may be in liquid form. That is, the food includes beverages. There is no limitation in particular in the manufacturing method of the foodstuff containing the composition of this invention. For example, blending, cooking, processing, and the like may be in accordance with those of general foods and can be produced by their production method, and the obtained food may contain the above-described composition of the present invention. Although the present invention is not particularly limited, the food of the present invention is preferably used in a manner that the intake of chalcone in tomorrow per day is preferably 0.5 mg to 100 mg, more preferably 2 mg to 25 mg. It is preferable to prepare so that the amount of per isoflavone intake is preferably 0.5 mg to 100 mg, more preferably 2 mg to 25 mg.
本発明の医薬は、本発明の組成物を含む。本発明の医薬は、優れたアディポネクチン産生誘導作用を有することから、低アディポネクチン血症治療剤又は予防剤、シンドロームＸ若しくはメタボリックシンドロームの治療剤又は予防剤、並びに低アディポネクチン血症に起因する、糖尿病、糖尿病合併症（網膜症、腎症、神経症、白内障、冠動脈疾患を含む）、高血圧症、肥満、及び／又は動脈硬化症の治療剤又は予防剤として有用である。 The medicament of the present invention comprises the composition of the present invention. Since the medicament of the present invention has an excellent adiponectin production-inducing action, the therapeutic agent or preventive agent for hypoadiponectinemia, the therapeutic agent or prophylactic agent for syndrome X or metabolic syndrome, and diabetes caused by hypoadiponectinemia, It is useful as a therapeutic or prophylactic agent for diabetic complications (including retinopathy, nephropathy, neurosis, cataract, coronary artery disease), hypertension, obesity, and / or arteriosclerosis.
本発明のアディポネクチン産生誘導剤は、本発明の組成物を含む。本発明のアディポネクチン産生誘導剤は、食品、医薬、飼料、及び研究用試薬のいずれの用途にも用いることができ、好適には医薬として用いることができる。 The adiponectin production inducer of the present invention contains the composition of the present invention. The adiponectin production inducer of the present invention can be used for any of food, medicine, feed, and research reagents, and can be preferably used as a medicine.
また、明日葉のトウ茎の裁断乾燥物を抽出原料とした固液抽出工程を包含することを特徴とする、カルコン含有抽出物の製造方法や、当該製造方法によって得られるカルコン含有抽出物、及び当該抽出物を含有するカルコン含有オイルも本発明の一態様である。本明細書において明日葉のトウ茎とは、草齢を重ねてトウ（花茎）が伸びきって固くなった明日葉の茎のことをいう。トウが伸びきった明日葉の茎は、その固さのために食用としては適さず、未利用であった。ところが驚くべきことに、本願発明者らは、明日葉のカルコンを含有する抽出物の原料として明日葉のトウ茎を用いることにより、これまで明日葉のカルコンを含有抽出物の原料として用いられてきた明日葉の葉と比べてもむしろ高い濃度のカルコンを含有する抽出物が得られることを見出した。 Further, a method for producing a chalcone-containing extract characterized by including a solid-liquid extraction step using a cut dry product of tomato stems of tomorrow leaves, and a chalcone-containing extract obtained by the production method, and A chalcone-containing oil containing the extract is also an embodiment of the present invention. In the present specification, the tow stem of tomorrow leaves refers to the stem of tomorrow leaves in which the tow (flower stalk) has been stretched and solidified with age. The stems of tomorrow's leaves where the tows were fully stretched were not suitable for food due to their firmness and were unused. Surprisingly, however, the inventors of the present application have used tomorrow leaf chalcone as a raw material for extracts containing tomorrow leaf chamocon as a raw material for extracts containing tomorrow leaf chalcones. It was found that an extract containing a higher concentration of chalcone was obtained than the leaves of tomorrow.
以下に実施例により本発明を具体的に説明するが、本発明はそれらの例により限定されない。 EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.
実施例１ 明日葉カルコンとイソフラボンによるアディポネクチンｍＲＮＡ発現増強作用
前駆脂肪細胞の脂肪細胞への分化誘導はＲｕｂｉｎ Ｃ．Ｓ．らの方法（ＪＢＣ．２５５ ７５７０−７５７８，１９７８）を一部改良して行った。２００μＭアスコルビン酸を含む１０％ウシ血清（大日本製薬社製）含有ダルベッコ改良イーグル培地（シグマ社製，Ｄ６０４６）に前駆脂肪細胞株３Ｔ３−Ｌ１（ヒューマンサイエンス研究資源バンク ＪＣＲＢ９０１４）を０．８×１０４個／ｍＬになるように懸濁し、１２穴マイクロタイタープレートのウェルに２ｍＬずつ加えて５％炭酸ガス存在下、３７℃で７日間培養した。なお、２日目と４日目には同培地による培地交換を行った。７日間の培養終了後、２００μＭアスコルビン酸を含む１０％ウシ胎児血清（Ｉｎｖｉｔｒｏｇｅｎ社製）含有ダルベッコ改良イーグル培地（以下Ａ−Ｄ−ＭＥＭ培地）にて培地交換を行った後、デキサメタゾンを終濃度０．２５μＭとなるように添加した。さらに、明日葉のカルコンとして国際公開第２００５／０７４９０６号パンフレットの実施例１及び２に記載の方法に従って調製した４−ヒドロキシデリシン（４ＨＤ）を下記の表１〜７に示す終濃度となるように、イソフラボンとしてダイゼイン（ＳＩＧＭＡ社製）、ビオカニンＡ（ＡＸＸＯＲＡ社製）、ダイジン（ＬＣ Ｌａｂｏｒａｔｏｒｉｅｓ社製）、ゲニスチン（ＬＣ Ｌａｂｏｒａｔｏｒｉｅｓ社製）、グリシテイン（長良サイエンス社製）、グリシチン（長良サイエンス社製）及び市販のイソフラボン含有粉末〔大豆抽出物（ダイゼインを約１７重量％、ゲニステインを約４重量％、及びグリシテインを約１３重量％含有）〕をそれぞれ表１〜７に示す終濃度となるように添加した。なお、陰性対照としてジメチルスルホキシド添加の区分を設定した。２日後にＡ−Ｄ−ＭＥＭ培地にて培地交換を行った後、再度表１〜７に示す終濃度となるように４ＨＤ及び／又はイソフラボンを各培養物に対してそれぞれ添加（陰性対照にはジメチルスルホキシドを添加）し、さらに３日間培養した。
Example 1 Adiponectin mRNA expression enhancing action by Asaba chalcone and isoflavone Induction of differentiation of preadipocytes into adipocytes was carried out by Rubin C. et al. S. The method (JBC. 255 7570-7578, 1978) was partially improved. Duplicated Dulbecco's modified Eagle's medium (Sigma, D6046) containing 10% bovine serum (Dainippon Pharmaceutical Co., Ltd.) containing 200 μM ascorbic acid, 0.8 × 10 The suspension was suspended at 4 cells / mL, 2 mL was added to each well of a 12-well microtiter plate, and the cells were cultured at 37 ° C. for 7 days in the presence of 5% carbon dioxide gas. On the second and fourth days, the medium was changed with the same medium. After completion of the culture for 7 days, the medium was exchanged with Dulbecco's modified Eagle medium (hereinafter referred to as AD-MEM medium) containing 10% fetal bovine serum (Invitrogen) containing 200 μM ascorbic acid, and dexamethasone was added at a final concentration of 0. It added so that it might become 25 micromol. Furthermore, 4-hydroxyderricin (4HD) prepared according to the method described in Examples 1 and 2 of International Publication No. 2005/074906 pamphlet as tomorrow's chalcone has the final concentrations shown in Tables 1 to 7 below. In addition, daidzein (manufactured by SIGMA), biocanin A (manufactured by AXXORA), daidzin (manufactured by LC Laboratories), genistin (manufactured by LC Laboratories), glycitein (manufactured by Nagara Science), glycitin (manufactured by Nagara Science) as isoflavones And commercially available isoflavone-containing powder (soybean extract (containing about 17% by weight of daidzein, about 4% by weight of genistein and about 13% by weight of glycitein)) were added so as to have final concentrations shown in Tables 1 to 7, respectively. did. In addition, the division of dimethyl sulfoxide addition was set as a negative control. Two days later, the medium was changed with the AD-MEM medium, and 4HD and / or isoflavone was added to each culture again so that the final concentrations shown in Tables 1 to 7 were obtained (as a negative control). Dimethyl sulfoxide was added), and further cultured for 3 days.
培養終了後、培地を除き０．５ｍＬのＲＮＡｉｓｏ Ｐｌｕｓ（タカラバイオ社製）を加え、細胞を１．５ｍＬのエッペンチューブに回収した。室温で５分間放置した後、０．１ｍＬのクロロホルムを加え、乳白色になるまでよく振り混ぜた。さらに室温で５分間放置した後、１０，０００ｒｐｍ、１５分間、４℃で遠心し、上清を別のエッペンチューブに移した。これに０．２５ｍＬのイソプロパノールを加え、よく混合し、室温で１０分間放置した。１０，０００ｒｐｍ、１０分間、４℃で遠心し、得られた沈殿を０．５ｍＬの７５％ＥｔＯＨで洗浄した。１０，０００ｒｐｍ、５分間、４℃で遠心後、沈殿を乾燥させた。１５μＬの注射用水で溶解し、ｔｏｔａｌ ＲＮＡ水溶液を得た。 After completion of the culture, the medium was removed, 0.5 mL of RNAiso Plus (manufactured by Takara Bio Inc.) was added, and the cells were collected in a 1.5 mL Eppendorf tube. After standing at room temperature for 5 minutes, 0.1 mL of chloroform was added and shaken and mixed well until milky white. The mixture was further left at room temperature for 5 minutes, centrifuged at 10,000 rpm for 15 minutes at 4 ° C., and the supernatant was transferred to another Eppendorf tube. To this was added 0.25 mL of isopropanol, mixed well and left at room temperature for 10 minutes. Centrifugation was performed at 10,000 rpm for 10 minutes at 4 ° C., and the resulting precipitate was washed with 0.5 mL of 75% EtOH. After centrifugation at 10,000 rpm for 5 minutes at 4 ° C., the precipitate was dried. It was dissolved in 15 μL of water for injection to obtain a total RNA aqueous solution.
逆転写反応およびリアルタイムＰＣＲは、ＰｒｉｍｅＳｃｒｉｐｔ（登録商標）ＲＴ ｒｅａｇｅｎｔ Ｋｉｔ（Ｐｅｒｆｅｃｔ Ｒｅａｌ Ｔｉｍｅ）（タカラバイオ社製）を用いて行った。リアルタイムＰＣＲは、ＳＹＢＲ（登録商標）Ｐｒｅｍｉｘ ＥｘＴａｑ ＩＩ（Ｐｅｒｆｅｃｔ Ｒｅａｌ Ｔｉｍｅ）（タカラバイオ社製）を用いて行った。リアルタイムＰＣＲは、ｍｏｕｓｅ Ａｄｉｐｏｎｅｃｔｉｎ遺伝子に特異的なプライマー対と、対照としてｍｏｕｓｅ β−Ａｃｔｉｎ遺伝子に特異的なプライマー対を用いた。ｍｏｕｓｅ Ａｄｉｐｏｎｅｃｔｉｎ遺伝子に特異的なプライマー対の配列を配列番号：１及び配列番号：２に、ｍｏｕｓｅ β−Ａｃｔｉｎ遺伝子に特異的なプライマー対の配列を配列番号：３及び配列番号：４に示す。測定は、Ｔｈｅｒｍａｌ Ｃｙｃｌｅｒ Ｄｉｃｅ（登録商標） Ｒｅａｌ Ｔｉｍｅ Ｓｙｓｔｅｍ（タカラバイオ社製）を用いて行った。測定は、全て３連で行った。なお、各ｍＲＮＡの発現量は、陰性対照区分のｍＲＮＡ発現量に対する相対量として下記の式により算出した。 Reverse transcription reaction and real-time PCR were performed using PrimeScript (registered trademark) RT reagent Kit (Perfect Real Time) (manufactured by Takara Bio Inc.). Real-time PCR was performed using SYBR (registered trademark) Premix ExTaq II (Perfect Real Time) (manufactured by Takara Bio Inc.). The real-time PCR used a primer pair specific for the mouse Adiponectin gene and a primer pair specific for the mouse β-Actin gene as a control. The sequence of the primer pair specific to the mouse Adiponectin gene is shown in SEQ ID NO: 1 and SEQ ID NO: 2, and the sequence of the primer pair specific to the mouse β-Actin gene is shown in SEQ ID NO: 3 and SEQ ID NO: 4. The measurement was performed using a Thermal Cycler Dice (registered trademark) Real Time System (manufactured by Takara Bio Inc.). All measurements were performed in triplicate. In addition, the expression level of each mRNA was computed by the following formula as a relative quantity with respect to the mRNA expression level of a negative control classification.
この結果を以下の表１〜７に示す。すなわち、表１〜７は明日葉のカルコンおよび各種イソフラボンを添加した細胞におけるＡｄｉｐｏｎｅｃｔｉｎのｍＲＮＡ発現の量比を示すものであり、明日葉のカルコンと各種イソフラボンを共添加することでＡｄｉｐｏｎｅｃｔｉｎのｍＲＮＡ発現量が相乗的に増加することが明らかとなった。 The results are shown in Tables 1 to 7 below. That is, Tables 1 to 7 show the amount ratio of mRNA expression of Adipontin in cells to which tomorrow leaf chalcone and various isoflavones were added. Was found to increase synergistically.
比較例 明日葉の葉からのカルコン粉末の調製
収穫した生明日葉（草齢０．５〜１．５年）の葉を裁断後、熱風で乾燥した。乾燥した明日葉５０ｇを熱水０．６Ｌで、３０分間抽出した。残渣の明日葉について、９０％エタノール０．６Ｌで４時間の還流抽出を行った。抽出液と残渣に分け、抽出液に対固形量３０％の活性炭を添加し、１時間処理を行った。珪藻土を用いて濾過を行い、カルコン抽出脱色液を得た。このカルコン抽出脱色液を減圧濃縮し、約１／１０になったところで加工澱粉を対固形量で等量添加した。さらに当初の１／２０まで減圧濃縮を行い、得られた濃縮液を減圧乾燥した。乾燥後１１．３ｇのカルコン粉末を得た。このカルコン粉末のカルコン濃度は、７．０ｍｇ／ｇであった。
Comparative Example Preparation of chalcone powder from leaves of tomorrow leaves After harvested raw tomorrow leaves (grass age 0.5 to 1.5 years) were cut and dried with hot air. 50 g of dried tomorrow leaves were extracted with 0.6 L of hot water for 30 minutes. The residue tomorrow was subjected to reflux extraction with 0.6 L of 90% ethanol for 4 hours. The extract was divided into the extract and the residue, and activated carbon with a solid content of 30% was added to the extract and treated for 1 hour. Filtration was performed using diatomaceous earth to obtain a chalcone extraction decolorizing solution. This chalcone extraction decoloring solution was concentrated under reduced pressure, and when it became about 1/10, the processed starch was added in an equal amount with respect to the solid amount. Further, the solution was concentrated under reduced pressure to 1/20 of the original, and the resulting concentrated solution was dried under reduced pressure. After drying, 11.3 g of chalcone powder was obtained. The chalcone concentration of this chalcone powder was 7.0 mg / g.
実施例２ 明日葉トウ茎からのカルコン粉末の調製
収穫した生明日葉（草齢１〜３年）のトウ茎を裁断後、熱風で乾燥した。乾燥した明日葉１００ｇを熱水２Ｌで、４５分間抽出した。残渣の明日葉について、９０％エタノール３０００ｍＬで４時間の還流抽出を行った。抽出液と残渣に分け、抽出液に対固形量５％の活性炭を添加し、１時間処理を行った。珪藻土を用い濾過を行い、カルコン抽出脱色液を得た。このカルコン抽出脱色液を減圧濃縮し、約１／１０になったところで加工澱粉を対固形量で等量添加した。さらに当初の１／２０まで減圧濃縮を行い、得られた濃縮液を減圧乾燥した。乾燥後１６．７ｇのカルコン粉末を得た。このカルコン粉末のカルコン濃度は、１７．１ｍｇ／ｇであった。
Example 2 Preparation of chalcone powder from tomorrow leaves tow stems Harvested fresh tomorrow leaves (1 to 3 years old) were cut and dried with hot air. 100 g of dried tomorrow leaves were extracted with 2 L of hot water for 45 minutes. The residue tomorrow was subjected to reflux extraction with 90% ethanol 3000 mL for 4 hours. The extract was divided into an extract and a residue, and activated carbon with a solid content of 5% was added to the extract and treated for 1 hour. Filtration was performed using diatomaceous earth to obtain a chalcone extraction decolorizing solution. This chalcone extraction decoloring solution was concentrated under reduced pressure, and when it became about 1/10, the processed starch was added in an equal amount with respect to the solid amount. Further, the solution was concentrated under reduced pressure to 1/20 of the original, and the resulting concentrated solution was dried under reduced pressure. After drying, 16.7 g of chalcone powder was obtained. The chalcone concentration of this chalcone powder was 17.1 mg / g.
本実施例により、明日葉のトウ茎を原料として用いることによって、明日葉の葉を原料として用いる従来の方法に比べて倍以上高い濃度のカルコンを含有する明日葉由来の組成物が得られることが明らかになった。 According to the present example, by using tomato stems of tomorrow leaves as a raw material, a composition derived from tomorrow leaves containing chalcone at a concentration twice or more higher than the conventional method using the leaves of tomorrow leaves as a raw material is obtained. Became clear.
実施例３ 明日葉トウ茎からのカルコンオイルの調製
収穫した生明日葉（草齢１〜３年）のトウ茎を裁断後、熱風で乾燥した。乾燥した明日葉２７０ｇを熱水５Ｌで、４５分間抽出した。残渣の明日葉について、９０％エタノール８Ｌで、４時間の還流抽出を行った。抽出液と残渣に分け、抽出液に対固形量５％の活性炭を添加し、１時間処理を行った。珪藻土を用い濾過を行い、カルコン抽出脱色液を得た。このカルコン抽出脱色液に中鎖脂肪酸トリグリセライドを対固形量で２倍量添加した。エタノール及び水がなくなるまで減圧濃縮を行い、静置後、５０ｇのカルコンオイルを得た。このカルコンオイルのカルコン濃度は、１８．１ｍｇ／ｇであった。
Example 3 Preparation of chalcone oil from tomorrow leaves tow stems Harvested raw tomorrow leaves (1 to 3 years old) were cut and then dried with hot air. 270 g of dried tomorrow leaves were extracted with 5 L of hot water for 45 minutes. The residue tomorrow was subjected to reflux extraction for 4 hours with 8 L of 90% ethanol. The extract was divided into an extract and a residue, and activated carbon with a solid content of 5% was added to the extract and treated for 1 hour. Filtration was performed using diatomaceous earth to obtain a chalcone extraction decolorizing solution. To this chalcone extraction and decolorization solution, medium-chain fatty acid triglyceride was added in an amount twice as much as the solid amount. Concentration was performed under reduced pressure until ethanol and water disappeared, and after standing, 50 g of chalcone oil was obtained. The chalcone oil had a chalcone concentration of 18.1 mg / g.
実施例４ 明日葉トウ茎からのカルコン粉末の調製２
収穫した生明日葉（草齢１〜３年）のトウ茎を裁断後、熱風で乾燥した。乾燥した明日葉１０ｇを熱水８００ｍＬで、３０分間抽出した。残渣の明日葉について、９０％エタノール２００ｍＬで１時間の抽出を行った。抽出液と残渣に分け、残渣についてさらに７０％エタノール２００ｍＬで１時間の抽出を行った。抽出液と残渣に分け、２回分の抽出液を合わせ、カルコン抽出液とした。このカルコン抽出液に乳化剤を対固形量で０．１割添加し、減圧濃縮を行った。約１／１０になったところで加工澱粉を対固形量で等量添加した。得られた濃縮液を凍結乾燥した。乾燥後１．３ｇのカルコン粉末を得た。このカルコン粉末のカルコン濃度は、２７．７ｍｇ／ｇであった。
Example 4 Preparation 2 of chalcone powder from tomato stems of tomorrow leaves
The harvested raw tomorrow leaves (1 to 3 years old) were cut and then dried with hot air. 10 g of dried tomorrow leaves were extracted with 800 mL of hot water for 30 minutes. About the tomorrow leaf of residue, extraction was performed for 1 hour with 200 mL of 90% ethanol. The residue was divided into an extract and a residue, and the residue was further extracted with 200 mL of 70% ethanol for 1 hour. Divided into the extract and residue, the two extracts were combined to obtain a chalcone extract. To this chalcone extract, 0.1% of the emulsifier was added in solid amount, and concentrated under reduced pressure. When about 1/10, the processed starch was added in an equal amount to the solid amount. The resulting concentrated solution was lyophilized. After drying, 1.3 g of chalcone powder was obtained. The chalcone concentration of this chalcone powder was 27.7 mg / g.
実施例５ 明日葉トウ茎からのカルコンオイルの調製２
収穫した生明日葉（草齢１〜３年）のトウ茎を裁断後、熱風で乾燥した。乾燥した明日葉１０ｇを熱水８００ｍＬで３０分間抽出した。残渣の明日葉について、９０％エタノール２００ｍＬで１時間の抽出を行った。抽出液と残渣に分け、残渣についてさらに７０％エタノール２００ｍＬで１時間の抽出を行った。これを抽出液と残渣に分け、２回分の抽出液を合わせ、カルコン抽出液とした。このカルコン抽出液にオリーブオイルを対固形量で２倍量添加した。エタノール及び水がなくなるまで減圧濃縮を行った後、遠心分離（３０００ｒｐｍ、１０分）を行い、１ｇのカルコンオイルを得た。このカルコンオイルのカルコン濃度は、３２．７ｍｇ／ｇであった。
Example 5 Preparation 2 of chalcone oil from tomato stems of tomorrow
The harvested raw tomorrow leaves (1 to 3 years old) were cut and then dried with hot air. 10 g of dried tomorrow leaves were extracted with 800 mL of hot water for 30 minutes. About the tomorrow leaf of residue, extraction was performed for 1 hour with 200 mL of 90% ethanol. The residue was divided into an extract and a residue, and the residue was further extracted with 200 mL of 70% ethanol for 1 hour. This was divided into an extract and a residue, and the two extracts were combined to obtain a chalcone extract. To this chalcone extract, olive oil was added twice as much as solids. After concentration under reduced pressure until ethanol and water disappeared, centrifugation (3000 rpm, 10 minutes) was performed to obtain 1 g of chalcone oil. The chalcone oil had a chalcone concentration of 32.7 mg / g.
実施例６ 明日葉のカルコンとイソフラボンを含有する組成物の調製１
実施例２と同様にして、乾燥した明日葉トウ茎１０ｋｇから、カルコン粉末１．８ｋｇ（明日葉のカルコンを３１ｇ含有）を得た。このカルコン粉末１８ｋｇに対して大豆抽出物（ダイゼイン１８重量％含有）をそれぞれ６０ｇ、１９０ｇ、４００ｇ添加し、混合機により均一にして明日葉のカルコン及びイソフラボンを含有する３種類の組成物を得た。
Example 6 Preparation 1 of a composition containing chalcone of tomorrow and isoflavone 1
In the same manner as in Example 2, 1.8 kg of chalcone powder (containing 31 g of chalcone of tomorrow leaves) was obtained from 10 kg of dried tomato stems. 60 g, 190 g and 400 g of soybean extract (containing 18% by weight of daidzein) were added to 18 kg of the chalcone powder, respectively, and three kinds of compositions containing tomorrow chalcone and isoflavone were obtained by using a mixer. .
実施例７ 明日葉のカルコンとイソフラボンを含有する組成物の調製２
実施例３と同様にして、乾燥した明日葉トウ茎１０ｋｇから、カルコンオイル１．９ｋｇ（明日葉のカルコンを３６ｇ含有）を得た。このカルコンオイル１．９ｋｇにグリセリン脂肪酸エステルを１５０ｇ添加したものに対して、さらに大豆抽出物（ダイゼイン１８重量％含有）をそれぞれ６５ｇ、２００ｇ、４１０ｇ添加し、撹拌機により均一にして明日葉のカルコン及びイソフラボンを含有する３種類の組成物を得た。
Example 7 Preparation 2 of a Composition Containing Tomorrow's Chalcone and Isoflavone 2
In the same manner as in Example 3, 1.9 kg of chalcone oil (containing 36 g of chalcone of tomorrow leaves) was obtained from 10 kg of dried tomato stems. To 1.9 kg of this chalcone oil, 150 g of glycerin fatty acid ester is added, and then 65 g, 200 g and 410 g of soybean extract (containing 18% by weight of daidzein) are added, respectively, and homogenized with a stirrer tomorrow's chalcone And three compositions containing isoflavones were obtained.
実施例８ 明日葉のカルコン及びイソフラボンを含有する錠剤の調製
下記表８に、本発明の組成物を錠剤にする場合の配合例を挙げる。なお、明日葉のカルコンとイソフラボンの組成物は実施例６で調製した３種類から選択し、使用する。
Example 8 Preparation of Tablets Containing Tomorrow's Chalcone and Isoflavone Table 8 below lists formulation examples when the composition of the present invention is made into tablets. The composition of tomorrow's chalcone and isoflavone is selected from the three types prepared in Example 6 and used.
実施例９ 明日葉のカルコン及びイソフラボンを含有する顆粒状食品の調製
実施例６で調製した明日葉のカルコンとイソフラボンを含有する３種類の組成物に、賦形剤を混合し、流動層造粒機又は押出し造粒機により造粒し、振動篩で整粒して顆粒状食品を製造する。
Example 9 Preparation of granular food containing tomorrow chalcone and isoflavone Three types of compositions containing tomorrow chalcone and isoflavone prepared in Example 6 were mixed with excipients and fluidized bed granulation. Granulated by a machine or extrusion granulator and sized with a vibrating sieve to produce a granular food.
実施例１０ 明日葉のカルコン及びイソフラボンを含有するハードカプセル状食品の調製
実施例６で調製した明日葉のカルコンとイソフラボンを含有する３種類の組成物に、賦形剤を混合し、ハードカプセルに充填して製造する。
Example 10 Preparation of hard capsule food containing tomorrow chalcone and isoflavone Three kinds of compositions containing tomorrow chalcone and isoflavone prepared in Example 6 were mixed with excipients and filled into hard capsules. Manufactured.
実施例１１ 明日葉のカルコン及びイソフラボンを含有するソフトカプセルの調製
下記表９に、本発明の組成物をソフトカプセルに内包させる場合の配合例を挙げる。なお、明日葉のカルコンとイソフラボンを含有する組成物は前記の実施例７において調製した３種類から選択し、使用する。
Example 11 Preparation of Soft Capsules Containing Tomorrow's Chalcone and Isoflavone Table 9 below lists formulation examples when encapsulating the composition of the present invention in soft capsules. In addition, the composition containing the chalcone of tomorrow and isoflavone is selected from the three types prepared in Example 7 and used.
実施例１２ 明日葉のカルコン及びイソフラボンを含有するゼリー状パウチ食品の調製
下記表１０のカルコンとイソフラボンを含有する組成物は実施例７で調製した３種類から選択し、使用する。
Example 12 Preparation of Jelly Pouch Food Containing Tomorrow's Chalcone and Isoflavone The composition containing chalcone and isoflavone shown in Table 10 below is selected from the three types prepared in Example 7 and used.
実施例１３ 明日葉のカルコン及びイソフラボンを含有する食パンの作製
実施例２で調製したカルコン粉末５００ｍｇと大豆抽出物（ダイゼインを約１７重量％、ゲニステインを約４重量％、及びグリシテインを約１３重量％含有）６０ｍｇとを混合し、明日葉のカルコン及びイソフラボンを含有する組成物を調製する。この組成物に対して、さらに強力粉２００ｇ、砂糖１５ｇ、脱粉（牛乳からパターをとった残りを乾燥粉末にしたもの）６ｇ、食塩３ｇ、天然酵母４ｇ、水１３６ｇを加えて混合し、よく捏ねてパンの生地とし、定法に従って食パン一斤を作製する。
Example 13 Preparation of bread containing tomorrow chalcone and isoflavone 500 mg of chalcone powder prepared in Example 2 and soybean extract (about 17% by weight daidzein, about 4% by weight genistein and about 13% by weight glycitein) Contain) 60 mg is mixed to prepare a composition containing tomorrow leaf chalcone and isoflavone. Add to this composition 200 g of strong flour, 15 g of sugar, 6 g of pulverized powder (patter made from milk and put it into dry powder), 3 g of salt, 4 g of natural yeast and 136 g of water, and mix well. Make bread loaf according to the standard method.
本発明により明日葉のカルコン及びイソフラボンを含有する組成物が提供される。当該組成物は、優れたアディポネクチン産生誘導作用を有するため、食品、医薬の分野において特に有用である。また、本発明により、明日葉のカルコンを高濃度で含有する明日葉由来抽出物の製造方法が提供される。 The present invention provides a composition comprising tomorrow leaf chalcone and isoflavone. Since the composition has an excellent adiponectin production-inducing action, it is particularly useful in the fields of food and medicine. In addition, the present invention provides a method for producing an extract derived from tomorrow that contains chalcone of tomorrow in a high concentration.
SEQ ID NO:1 ; Primer to amplify the cDNA fragment of mouse Adiponectin gene.
SEQ ID NO:2 ; Primer to amplify the cDNA fragment of mouse Adiponectin gene.
SEQ ID NO:3 ; Primer to amplify the cDNA fragment of mouse Beta-Actin gene.
SEQ ID NO:4 ; Primer to amplify the cDNA fragment of mouse Beta-Actin gene.
SEQ ID NO: 1; Primer to amplify the cDNA fragment of mouse Adiponectin gene.
SEQ ID NO: 2; Primer to amplify the cDNA fragment of mouse Adiponectin gene.
SEQ ID NO: 3; Primer to amplify the cDNA fragment of mouse Beta-Actin gene.
SEQ ID NO: 4; Primer to amplify the cDNA fragment of mouse Beta-Actin gene.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011028361A JP5725649B2 (en) | 2010-02-19 | 2011-02-14 | Composition containing tomorrow chalcone and isoflavone |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010035139 | 2010-02-19 | ||
| JP2010035139 | 2010-02-19 | ||
| JP2011028361A JP5725649B2 (en) | 2010-02-19 | 2011-02-14 | Composition containing tomorrow chalcone and isoflavone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011190245A JP2011190245A (en) | 2011-09-29 |
| JP5725649B2 true JP5725649B2 (en) | 2015-05-27 |
Family
ID=44795537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011028361A Active JP5725649B2 (en) | 2010-02-19 | 2011-02-14 | Composition containing tomorrow chalcone and isoflavone |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5725649B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018013983A1 (en) * | 2016-07-15 | 2018-01-18 | Jbsl-Usa Inc. | Weight loss compound and method of extraction |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102715604B (en) * | 2012-06-25 | 2013-10-16 | 上海交通大学 | Ashitaba drink and preparation method thereof |
| CN104547548B (en) * | 2014-12-31 | 2018-05-29 | 林茂成 | The health liquor formula and its preparation process of a kind of tonifying kidney and strengthening yang |
| CN105362586A (en) * | 2015-12-01 | 2016-03-02 | 青岛麦瑞特医药技术有限公司 | Pharmaceutical composition for treating senile urinary incontinence |
| JP6726034B2 (en) * | 2016-06-08 | 2020-07-22 | 株式会社アイビー化粧品 | Fibroblast proliferation promoter |
| JP6985789B2 (en) * | 2016-08-03 | 2021-12-22 | 日本ハム株式会社 | Composition for enhancing adiponectin expression |
| JP7507460B2 (en) * | 2016-11-18 | 2024-06-28 | 株式会社東洋新薬 | Composition for preventing and/or improving menopausal symptoms |
| JP7141090B2 (en) * | 2018-05-25 | 2022-09-22 | 国立研究開発法人農業・食品産業技術総合研究機構 | Method for producing gluten-free rice flour bread containing isoflavone |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4846990B2 (en) * | 2003-08-06 | 2011-12-28 | 株式会社テラ・ブレインズ | Adiponectin secretion promoter |
| JP2006306800A (en) * | 2005-04-28 | 2006-11-09 | Kirin Brewery Co Ltd | Farnesoid x receptor activator |
| JP2007063207A (en) * | 2005-09-01 | 2007-03-15 | Noevir Co Ltd | Adiponectin production promoter |
| JP2007106718A (en) * | 2005-10-14 | 2007-04-26 | Sunstar Inc | Adiponectin secretion promoter and oral composition containing the adiponectin secretion promotor |
| JP2008031076A (en) * | 2006-07-28 | 2008-02-14 | Nippon Seibutsu Kagaku Kenkyusho:Kk | Adiponectin production enhancer |
-
2011
- 2011-02-14 JP JP2011028361A patent/JP5725649B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018013983A1 (en) * | 2016-07-15 | 2018-01-18 | Jbsl-Usa Inc. | Weight loss compound and method of extraction |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011190245A (en) | 2011-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5725649B2 (en) | Composition containing tomorrow chalcone and isoflavone | |
| Torres-León et al. | Mango seed: Functional and nutritional properties | |
| CA2854281C (en) | A muscle atrophy inhibitor | |
| US8828955B2 (en) | Glutathione production enhancer, prophylactic/therapeutic agent for diseases caused by glutathione deficiency, and food, beverage and feed | |
| KR101158856B1 (en) | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of Glycine max leaves as an active ingredient | |
| WO2004091642A1 (en) | Preventive or remedy for arthritis | |
| JP5066725B2 (en) | Fat absorption inhibitor, fat accumulation inhibitor or fat burning accelerator | |
| JP2009269889A (en) | Glutathione production promoter, agent for preventing or treating disease caused by deficiency of glutathione, and food and drink | |
| JPWO2004112817A1 (en) | Celery family-derived extract and method for producing the same | |
| JP2006045212A (en) | Oral composition containing specific quinic acid derivative | |
| JP7229513B2 (en) | Brain function improving agent and food and drink for improving brain function | |
| KR101368723B1 (en) | Composition and functional food for prevention and treatment of obesity | |
| JP2008163003A (en) | Fat absorption inhibitor | |
| JP2008163004A (en) | Fat accumulation inhibitor | |
| Nissar et al. | Nutritional composition and bioactive potential of watermelon seeds: a pathway to sustainable food and health innovation | |
| JP2009114158A (en) | Blood sugar level rising inhibitor | |
| JP6131275B2 (en) | IGF-1 production promoter | |
| KR20180098883A (en) | Composition for anti-obesity or reducing body-fat having extract of peanut sprouts as active component | |
| JP4623999B2 (en) | Aldose reductase activity inhibitor, preventive / therapeutic agent for diabetic complications, and food and drink for the prevention / treatment of diabetic complications | |
| KR102025572B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component | |
| JP4352030B2 (en) | healthy food | |
| JP2008163005A (en) | Fat combustion-promoting agent | |
| AU2006347121B2 (en) | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia | |
| KR20140070901A (en) | Composition for prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera seed as an active ingredient | |
| JP2010037258A (en) | Absorption promoter for polyphenol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150213 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150327 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150330 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5725649 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |